Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine

被引:76
作者
Wheaton, S
Tallman, MS
Hakimian, D
Peterson, L
机构
[1] NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611
[2] NORTHWESTERN UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,CHICAGO,IL 60611
关键词
D O I
10.1182/blood.V87.4.1556.bloodjournal8741556
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Minimal residual disease (MRD) can be detected in bone marrow core biopsies of patients with hairy cell leukemia (HCL) after treatment with 2-chlorodeoxyadenosine (2-CdA) using immunohistochemical (IHC) techniques. The purpose of this study was to determine whether the presence of MRD predicts bone marrow relapse. We studied paraffin-embedded bone marrow core biopsies from 39 patients with HCL in complete remission (CR) 3 months after a single cycle of 2-CdA. Biopsies performed 3 months posttherapy and annually thereafter were examined by routine hematoxylin and eosin (H&E) staining and IHC using the monoclonal antibodies (MoAbs) anti-CD45RO, anti-CD20, and DBA.44. At 3 months after therapy, 5 of 39 (13%) patients had MRD detectable by IHC that was not evident by routine H&E staining. Two of the five patients (40%) with MRD at 3 months have relapsed, whereas only 2 of 27 (7%) patients with no MRD and at least 1 year of follow up relapsed (P =.11). Over the 3-year follow-up period, two additional patients developed MRD. Overall, three of six (50%) patients with MRD detected at any time after therapy have relapsed, whereas only 1 of 25 (4%) patients without MRD has relapsed (P =.016). These data suggest that the presence of MRD after treatment with 2-CdA may predict relapse. (C) 1996 by The American Society of Hematology.
引用
收藏
页码:1556 / 1560
页数:5
相关论文
共 14 条
  • [1] Bastie J. N., 1994, British Journal of Haematology, V87, P209
  • [2] DICELLE PF, 1994, LEUKEMIA LYMPHOMA, V14, P139
  • [3] IMMUNOMORPHOLOGICAL ANALYSIS OF BONE-MARROW BIOPSIES AFTER TREATMENT WITH 2-CHLORODEOXYADENOSINE FOR HAIRY-CELL LEUKEMIA
    ELLISON, DJ
    SHARPE, RW
    ROBBINS, BA
    SPINOSA, JC
    LEOPARD, JD
    SAVEN, A
    PIRO, LD
    [J]. BLOOD, 1994, 84 (12) : 4310 - 4315
  • [4] ESTEY EH, 1992, BLOOD, V79, P882
  • [5] FILLEUL B, 1994, LEUKEMIA, V8, P1153
  • [6] GOLOMB H, 1983, BLOOD, V61, P369
  • [7] HAIRY CELL LEUKEMIA - CLINICAL REVIEW BASED ON 71 CASES
    GOLOMB, HM
    CATOVSKY, D
    GOLDE, DW
    [J]. ANNALS OF INTERNAL MEDICINE, 1978, 89 (05) : 677 - 683
  • [8] HAKIMIAN D, 1993, BLOOD, V82, P1798
  • [9] INVESTIGATION OF BONE-MARROW LYMPHOCYTE SUBSETS IN NORMAL, REACTIVE, AND NEOPLASTIC STATES USING PARAFFIN-EMBEDDED BIOPSY SPECIMENS
    HORNY, HP
    WEHRMANN, M
    GRIESSER, H
    TIEMANN, M
    BULTMANN, B
    KAISERLING, E
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1993, 99 (02) : 142 - 149
  • [10] HOUNIEU H, 1992, AM J CLIN PATHOL, V98, P26